Urothelial Carcinoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 49 expanded access programs, clinical trials, and compassionate use pathways listed for Urothelial Carcinoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with urothelial carcinoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 18 programs are currently active or recruiting, with the remaining 31 in other lifecycle stages. Sponsors actively running programs in this area include Memorial Sloan Kettering Cancer Center, UroGen Pharma Ltd., CG Oncology, Inc., Fox Chase Cancer Center, Genentech, Inc., and others.
By recruiting status
Snapshot of where every Urothelial Carcinoma program currently sits in its lifecycle.
- Active / Recruiting18
- Inactive31
Top sponsors
Organisations running the most Urothelial Carcinoma programs in the directory.
- Memorial Sloan Kettering Cancer Center4 programs
- UroGen Pharma Ltd.4 programs
- CG Oncology, Inc.2 programs
- Fox Chase Cancer Center2 programs
- Genentech, Inc.2 programs
- M.D. Anderson Cancer Center2 programs
- Mayo Clinic2 programs
- Seagen Inc.2 programs
- AbbVie1 program
- Acrivon Therapeutics1 program
Urothelial Carcinoma programs (49)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Phase 2 Study of Zanidatamab for Patients with HER2-positive Tumors — Jazz Pharmaceuticals
- Phase 3 Study of UGN-102 for Treating Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer — UroGen Pharma Ltd.
- Phase 3 Study of UGN-104 for Treating Low-Grade Upper Tract Urothelial Cancer — UroGen Pharma Ltd.
- Phase II Study of Atezolizumab with Cisplatin and Gemcitabine Before Bladder Cancer Surgery — Memorial Sloan Kettering Cancer Center
- Study on Erdafitinib for Patients with Advanced Urothelial Cancer — Janssen Research & Development, LLC
- Study on MT-4561 for Patients with Advanced Solid Tumors — Mitsubishi Tanabe Pharma America Inc.
- Study on Two Dosing Schedules of Atezolizumab with Gemcitabine and Cisplatin for First-Line Treatment of Metastatic Bladder Cancer — Memorial Sloan Kettering Cancer Center
- Study on ALE.P03 as a Single Treatment for Adults with Certain Advanced or Metastatic CLDN1+ Solid Tumors — Alentis Therapeutics AG
- Study on New Treatments for Advanced Urothelial Cancer Resistant to PD-1/L1 Inhibitors — Merck Sharp & Dohme LLC
- Study on Sacituzumab Govitecan and Nivolumab for High-Risk Muscle-Invasive Urothelial Carcinoma — University of California, Irvine
- Expanded Access Study of Atezolizumab for Advanced or Metastatic Urothelial Cancer After Platinum Chemotherapy Failure — Genentech, Inc.
- Study on Circulating Tumor DNA Response in Urothelial Cancer — University of Oklahoma
- Study on Gemcitabine and Carboplatin for Advanced Urothelial Cancer After Treatment with Enfortumab Vedotin and Pembrolizumab — Fox Chase Cancer Center
- Study on Gemcitabine and Docetaxel for High-Grade Bladder Cancer Unresponsive to BCG Treatment — Michael A. O'Donnell
- Study on Nivolumab With and Without Urelumab for Patients Unable to Take Cisplatin or Refusing Chemotherapy with Muscle-Invasive Bladder Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Enfortumab Vedotin and Pembrolizumab Before Surgery for Upper Tract Urothelial Cancer — University of Michigan Rogel Cancer Center
- Study on PF-08634404 Alone or with Enfortumab Vedotin for Urothelial Cancer — Pfizer
- Home-Based Cancer Treatment Program for Patients in the Florida Panhandle and Nearby Areas — Mayo Clinic
- Phase 2 Study of Pemetrexed, Etrumadenant, and Zimberelimab for Previously Treated Advanced Urothelial Cancer — M.D. Anderson Cancer Center
- Phase 3 Study of UGN-103 for Treating Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer — UroGen Pharma Ltd.
- Phase II Study Comparing Chemotherapy Alone to Chemotherapy Plus Durvalumab for Bladder Cancer with Lymph Node Involvement — M.D. Anderson Cancer Center
- Study on ACR-368 for Treating Ovarian, Endometrial, and Bladder Cancers — Acrivon Therapeutics
- A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT — CG Oncology, Inc.
- Study on BMS-986340 Alone and with Nivolumab or Docetaxel for Advanced Solid Tumors — Bristol-Myers Squibb
- A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 — Seagen Inc.
- A Study of Enfortumab Vedotin in People with Urothelial Carcinoma of the Upper Urinary Tract — Memorial Sloan Kettering Cancer Center
- Study on ICP-192 for Patients with Advanced Solid Tumors — Beijing InnoCare Pharma Tech Co., Ltd.
- Expanded Access Program for Cretostimogene Grenadenorepvec in Treating Bladder Cancer Unresponsive to BCG — CG Oncology, Inc.
- Expanded Access Study of Atezolizumab for Advanced or Metastatic Urothelial Cancer After Platinum Chemotherapy Failure — Genentech, Inc.
- Study Comparing In-Home and In-Clinic Administration of Nivolumab for Cancer Patients — Mayo Clinic
- Study on Disitamab Vedotin with Pembrolizumab vs Chemotherapy for Untreated Urothelial Cancer with HER2 Expression — Seagen Inc.
- Study on Enfortumab Vedotin and Pembrolizumab for Bladder Cancer — Memorial Sloan Kettering Cancer Center
- Study on Adjusting Enfortumab Vedotin Treatment Schedule for Advanced Urothelial Cancer — Fox Chase Cancer Center
- Study on LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab for Advanced or Metastatic Solid Tumors — PureTech
- Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder — Noah Hahn, M.D.
- Phase II Study of sEphB4-HSA and Pembrolizumab for Treating Solid Tumors — University of Southern California
- Access Program for Mitomycin Solution for Kidney and Urinary Tract Cancer — UroGen Pharma Ltd.
- Study on Pembrolizumab for Muscle-Invasive Bladder Cancer — Matthew Galsky
- Study on New Treatment for Advanced Solid Tumors Resistant to Standard Therapies — Klus Pharma Inc.
- Study on PRO1107 for Patients with Advanced Solid Tumors — Genmab
- Study on Combination Immunotherapies for Patients Previously Treated with Immune Checkpoint Inhibitors — ImmunityBio, Inc.
- Study on the Safety and Effectiveness of NEO212 for Patients with Certain Brain Tumors or Brain Metastasis — Neonc Technologies, Inc.
- Study on the Safety and Early Effects of TYRA-300 in Advanced Bladder Cancer and Other Tumors with FGFR3 Gene Changes — Tyra Biosciences, Inc
- Study on the Safety and Effects of ONC-392 Alone and with Anti-PD-1 in Advanced Solid Tumors and Non-Small Cell Lung Cancer — OncoC4, Inc.
- Study on the Effectiveness and Safety of Various Immunotherapy Treatments for Urothelial Carcinoma (MORPHEUS-UC) — Hoffmann-La Roche
- Study on CBX-12 for Patients with Advanced or Metastatic Solid Tumors — Cybrexa Therapeutics
- Study on INBRX-106 Alone and with Pembrolizumab (Keytruda®) for Advanced Solid Tumors — Inhibrx Biosciences, Inc
- Study on the Safety and Effects of Livmoniplimab and Budigalimab for Treating Urothelial Carcinoma — AbbVie
- Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer — National Cancer Institute (NCI)
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Urothelial Carcinoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.